IADR Abstract Archives
Antimicrobials in Temporary Resilient Liner: A Promising Denture Stomatitis Treatment
Objectives: This randomized clinical study aimed to evaluate the long-term efficacy of a temporary denture resilient liner (Trusoft) modified by the addition of minimum inhibitory concentrations (MICs) of antimicrobial agents for Candida albicans biofilm in the denture stomatitis (DS) treatment.
Methods: Forty patients with DS and users of maxillary complete denture (MCD) were randomly assigned to one of treatments during 14 days (n=10): Positive Control-PC: nystatin oral suspension (100,000IU/mL; 4x/day); General Control-GC: MCD relining with Trusoft, and NYS, and CHX: MCD relining with Trusoft containing nystatin and chlorhexidine diacetate at MICs, respectively. The treatment effectiveness was evaluated by cytological smears and mycological quantitative cultures taken from the palates and dentures of all patients before (baseline), at the end of treatment (day 14) and 15, 30, and 60 days after its suspension. Clinical response was investigated by photographs taken from the palates at each visit. Data were analyzed with the use of a series of statistical tests (α=0.05).
Results: Palatal smears of NYS and CHX exhibited no mycelial Candida (0%) on day 14 and, on the last day follow-up, only 1 patient from CHX demonstrated its presence. MCD smears showed a significant reduction in mycelial forms for all groups on day 14 (P<0.05), but this difference was maintained at follow-up only for the groups with relined dentures (P<0.05). Only mycological cultures from palates of NYS and dentures from NYS and CHX showed reduction in the CFU/mL values after 14 days and follow-up (P<0.05). Patients from both controls exhibited no clinical improvement in DS severity on day 14 (P>0.05), which was observed significantly for NYS and CHX, and these scores were maintained at follow-up (P<0.05).
Conclusions: The addition of nystatin and chlorhexidine at their MICs to a temporary resilient liner was a long-term effective treatment for DS, with superior results to conventional therapy with nystatin suspension.
Methods: Forty patients with DS and users of maxillary complete denture (MCD) were randomly assigned to one of treatments during 14 days (n=10): Positive Control-PC: nystatin oral suspension (100,000IU/mL; 4x/day); General Control-GC: MCD relining with Trusoft, and NYS, and CHX: MCD relining with Trusoft containing nystatin and chlorhexidine diacetate at MICs, respectively. The treatment effectiveness was evaluated by cytological smears and mycological quantitative cultures taken from the palates and dentures of all patients before (baseline), at the end of treatment (day 14) and 15, 30, and 60 days after its suspension. Clinical response was investigated by photographs taken from the palates at each visit. Data were analyzed with the use of a series of statistical tests (α=0.05).
Results: Palatal smears of NYS and CHX exhibited no mycelial Candida (0%) on day 14 and, on the last day follow-up, only 1 patient from CHX demonstrated its presence. MCD smears showed a significant reduction in mycelial forms for all groups on day 14 (P<0.05), but this difference was maintained at follow-up only for the groups with relined dentures (P<0.05). Only mycological cultures from palates of NYS and dentures from NYS and CHX showed reduction in the CFU/mL values after 14 days and follow-up (P<0.05). Patients from both controls exhibited no clinical improvement in DS severity on day 14 (P>0.05), which was observed significantly for NYS and CHX, and these scores were maintained at follow-up (P<0.05).
Conclusions: The addition of nystatin and chlorhexidine at their MICs to a temporary resilient liner was a long-term effective treatment for DS, with superior results to conventional therapy with nystatin suspension.